Hikma Pharmaceuticals PLC ADR (HKMPY)
Hikma Pharmaceuticals PLC ADR is a depositary receipt representing common stock of Hikma Pharmaceuticals PLC and trades on OTC Markets under the symbol HKMP.Y. Hikma Pharmaceuticals is a pharmaceutical company that develops, manufactures, markets, and sells generic, specialty, and branded medicines. Its operations are organized into three business segments: Injectables, Hikma Rx, and Branded. The Injectables business focuses on generic and specialty injectable medicines used mainly in hospitals, while Hikma Rx serves the retail market with oral, respiratory, and other generic and specialty products. The Branded segment includes branded generics and in-licensed products sold to retail and hospital customers. Hikma’s products span therapeutic areas such as respiratory care, oncology, and pain management, and are available in solid, semi-solid, liquid, and injectable forms. The company operates across the United Kingdom, Europe, North America, the Middle East, North Africa, and other international markets. Hikma Pharmaceuticals was founded in 1978 and is headquartered in London, United Kingdom.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Payment Date | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-HKMP.Y
|
$56.96
|
37.9% Upside
|
Undervalued
|
Not available
|
Not available
|
Great
|
September 28, 2026
|
4.1%
|
November 6, 2026
|
11.6x
|
1.8x
|
1.3x
|
4.508 B
|
6.192 B
|
30.1%
|
67.6%
|
8.7
|
47.5%
|
61.5%
|
